Ingevity (NYSE:NGVT – Get Free Report) had its price objective increased by Wells Fargo & Company from $65.00 to $75.00 in a report released on Friday,Benzinga reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s price target suggests a potential upside of 6.39% from the company’s current price.
Several other analysts also recently commented on NGVT. Wall Street Zen downgraded Ingevity from a “strong-buy” rating to a “buy” rating in a research note on Saturday, February 21st. Jefferies Financial Group reaffirmed a “buy” rating and issued a $82.00 price objective on shares of Ingevity in a research report on Thursday. Zacks Research raised Ingevity to a “hold” rating in a research report on Tuesday, December 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Ingevity in a research report on Thursday, January 22nd. Finally, BMO Capital Markets boosted their target price on shares of Ingevity from $64.00 to $70.00 and gave the company an “outperform” rating in a report on Wednesday, December 10th. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $75.67.
View Our Latest Analysis on NGVT
Ingevity Price Performance
Ingevity (NYSE:NGVT – Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported $0.58 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.16). The firm had revenue of $255.10 million during the quarter, compared to the consensus estimate of $257.27 million. Ingevity had a negative net margin of 13.51% and a positive return on equity of 100.39%. Ingevity’s revenue for the quarter was down 3.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.95 earnings per share. Ingevity has set its FY 2026 guidance at 4.800-5.20 EPS. As a group, research analysts forecast that Ingevity will post 4.45 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the business. Global Retirement Partners LLC bought a new position in shares of Ingevity in the fourth quarter worth $27,000. Oakworth Capital Inc. bought a new stake in shares of Ingevity during the 3rd quarter worth $28,000. Meeder Asset Management Inc. bought a new stake in Ingevity in the 4th quarter worth approximately $33,000. Kestra Advisory Services LLC bought a new position in shares of Ingevity during the 4th quarter valued at $47,000. Finally, Geneos Wealth Management Inc. boosted its holdings in Ingevity by 85.8% during the 2nd quarter. Geneos Wealth Management Inc. now owns 838 shares of the company’s stock valued at $36,000 after acquiring an additional 387 shares during the period. 91.59% of the stock is owned by institutional investors.
Ingevity Company Profile
Ingevity Corporation, traded as NGVT, is a specialty chemicals and performance materials company headquartered in North Charleston, South Carolina. The company operates two primary business units: Performance Chemicals and Performance Materials. The Performance Chemicals segment produces and markets specialty chemicals derived largely from wood and other natural feedstocks, including rosin acids, tall oil fatty acids and esters, as well as specialty petroleum resins. These products serve a broad range of industries, including paper, adhesives, coatings, oilfield drilling and consumer goods.
The Performance Materials segment develops and manufactures activated carbon products and composites for applications such as automotive emissions control, industrial air and water purification, and spill containment.
Further Reading
- Five stocks we like better than Ingevity
- The gold chart Wall Street is terrified of…
- America’s 1776 happening again
- This makes me furious
- Buy this Gold Stock Before May 2026
- What a Former CIA Agent Knows About the Coming Collapse
Receive News & Ratings for Ingevity Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ingevity and related companies with MarketBeat.com's FREE daily email newsletter.
